| Indication of trial | Phase of Trial | Role In Trial | Year |
|---|---|---|---|
| A phase IIb/III,Randomised, Double-blind, Placebo-Controlled, Multicentre, Study of CA-170 in combination with Chemotherapy in patients with Stage IV Non-Squamous Non-Small Cell lung Cancer. | Phase III | Principal Investigator | 2023 |
| An open label, Multi-Centre, Randomized, Two-Treatment, and Multi dose, parallel, Comparative Bioavailability Study of Bertezomib Injection 3.5mg/0.2ml and VECADE 3.5mg powder for solution for injection at a dose of .3mg/m2 in Multiple Myeloma Patients. | Phase-III | Co- Investigator | 2021 |
| A multi-centre, Double-Blind, randomized parallel Group, Active controlled, Two Part, Phase-III, Global Study to Evaluate the Pharmacokinetics, Effiacy,and Safety of BP 02 (Trastuzumab) in Comparison with Herceptin- EU in patients with Her2-positive Early Breast Cancer and Metastatic Breast Cancer. | Phase-III | Co- Investigator | 2019-2022 |
| Prospective , multi-center, randomized,double-blind,two-arm,parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR_045/Xgeva for prevention of skeletal related events in patients with bone metastases from solid tumours. | Phase-III | Co- Investigator | 2018-2019 |
| Metastatic Breast Cancer | Phase-III | Principal Investigator | 2017-2018 |
| A prospective , Multicenter, randomize, double blind, phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences LTD versus Innovator Bevacizumab both in combination with CAPEOX in Patients with Metastatic Colorectal Cancer | Phase-III | Principal Investigator | 2016-2017 |
| A randomized open label single dose two treatment three sequence partial replicate cross over multicenter bioequivalence study of Capecitabine 500 mg tablets with Xeloda in adult cancer patients under fed conditions- Completed US FDA inspection for the same. | Phase-III | Principal Investigator | 2018-2019 |
